Trials / Completed
CompletedNCT00185861
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety of delivering arsenic trioxide (ATO) in combination with stereotactic radiotherapy in recurrent malignant glioma by performing an open label, Phase I dose escalation trial. Results from this study will provide a basis for further study of ATO combined with radiation therapy as a radiosensitizer for malignant brain tumors in future Phase II studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arsenic Trioxide | |
| PROCEDURE | Stereotactic radiosurgery |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2008-01-01
- Completion
- 2009-04-01
- First posted
- 2005-09-16
- Last updated
- 2009-04-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00185861. Inclusion in this directory is not an endorsement.